Refine
Year of publication
Document Type
- Preprint (659)
- Article (448)
- Working Paper (1)
Language
- English (1108)
Has Fulltext
- yes (1108)
Is part of the Bibliography
- no (1108)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (7)
- Heavy-ion collision (6)
- Branching fraction (5)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- Quarkonium (4)
- ALICE experiment (3)
- BESIII (3)
- Charm physics (3)
- Electroweak interaction (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Lepton colliders (3)
- QCD (3)
- ALICE (2)
- Charmed mesons (2)
- Hadronic decays (2)
- Heavy Quark Production (2)
- Initial state radiation (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Particle Correlations and Fluctuations (2)
- Particle and Resonance Production (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- RHIC (2)
- e +-e − Experiments (2)
- e+-e− Experiments (2)
- pp collisions (2)
- 900 GeV (1)
- ADHD (1)
- ALICE detector (1)
- Anti-nuclei (1)
- BCX7353 (1)
- Beauty production (1)
- Bhabha (1)
- Boosted Jets (1)
- Brain (1)
- Branching fractions (1)
- C1 inhibitor (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Charmonia (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Collectivity (1)
- Comparison with QCD (1)
- Correlation (1)
- Course (1)
- Di-hadron correlations (1)
- Diagnosis (1)
- Diffraction (1)
- Elastic scattering (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Elliptic flow (1)
- Exotics (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flow (1)
- Form factors (1)
- Genetics (1)
- Groomed jet radius (1)
- HAE (1)
- HBT (1)
- HSV (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronic cross section (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Heavy-ion collisions (1)
- Hyperons (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- Material budget (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Muon anomaly (1)
- Neural network (1)
- Neutrinos (1)
- Nonflow (1)
- Nuclear modification factor (1)
- Outcome (1)
- PYTHIA (1)
- Particle phenomena (1)
- Pb–Pb (1)
- Pion form factor (1)
- Polarization (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton-proton collisions (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- R value (1)
- Rapidity Range (1)
- Rare decays (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- STAR (1)
- Shear viscosity (1)
- Single electrons (1)
- Single muons (1)
- SoftDrop (1)
- Spectroscopy (1)
- Spin alignment (1)
- Splitting function (1)
- Systematic Uncertainty (1)
- TR (1)
- Techniques Electromagnetic calorimeters (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- adalimumab (1)
- berotralstat (1)
- checkpoint proteins (1)
- clinical trial (1)
- dE/dx (1)
- detector (1)
- diphoton (1)
- ectosomes (1)
- efficacy (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- glioma (1)
- guidelines (1)
- head-to-head (1)
- heavy ion experiments (1)
- hereditary angioedema (1)
- ixekizumab (1)
- kallikrein inhibitor (1)
- long-term prophylaxis (1)
- luminosity (1)
- meson (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- multiplex immunofluorescence (1)
- oncolytic virotherapy (1)
- p+p collisions (1)
- prophylaxis (1)
- psoriatic arthritis (1)
- quark gluon plasma (1)
- reproducibility (1)
- rigor (1)
- safety (1)
- standardization (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1093)
- Frankfurt Institute for Advanced Studies (FIAS) (941)
- Informatik (905)
- Medizin (10)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Biowissenschaften (1)
- Center for Financial Studies (CFS) (1)
- ELEMENTS (1)
- Georg-Speyer-Haus (1)
The study of (anti-)deuteron production in pp collisions has proven to be a powerful tool to investigate the formation mechanism of loosely bound states in high-energy hadronic collisions. In this paper the production of (anti-)deuterons is studied as a function of the charged particle multiplicity in inelastic pp collisions at s√=13 TeV using the ALICE experiment. Thanks to the large number of accumulated minimum bias events, it has been possible to measure (anti-)deuteron production in pp collisions up to the same charged particle multiplicity (dNch/dη∼26) as measured in p–Pb collisions at similar centre-of-mass energies. Within the uncertainties, the deuteron yield in pp collisions resembles the one in p–Pb interactions, suggesting a common formation mechanism behind the production of light nuclei in hadronic interactions. In this context the measurements are compared with the expectations of coalescence and statistical hadronisation models (SHM).
The study of (anti-)deuteron production in pp collisions has proven to be a powerful tool to investigate the formation mechanism of loosely bound states in high energy hadronic collisions. In this paper the production of (anti-)deuterons is studied as a function of the charged particle multiplicity in inelastic pp collisions at s√=13 TeV using the ALICE experiment. Thanks to the large number of accumulated minimum bias events, it has been possible to measure (anti-)deuteron production in pp collisions up to the same charged particle multiplicity (dNch/dη∼26) as measured in p-Pb collisions at similar centre-of-mass energies. Within the uncertainties, the deuteron yield in pp collisions resembles the one in p-Pb interactions, suggesting a common formation mechanism behind the production of light nuclei in hadronic interactions. In this context the measurements are compared with the expectations of coalescence and Statistical Hadronisation Models (SHM).
The study of (anti-)deuteron production in pp collisions has proven to be a powerful tool to investigate the formation mechanism of loosely bound states in high energy hadronic collisions. In this paper the production of (anti-)deuterons is studied as a function of the charged particle multiplicity in inelastic pp collisions at s√=13 TeV using the ALICE experiment. Thanks to the large accumulated integrated luminosity, it has been possible to measure (anti-)deuteron production in pp collisions up to the same charged particle multiplicity (dNch/dη∼26) as measured in p-Pb collisions at similar centre-of-mass energies. Within the uncertainties, the deuteron yield in pp collisions resembles the one in p-Pb interactions, suggesting a common formation mechanism behind the production of light nuclei in hadronic interactions. In this context the measurements are compared with the expectations of coalescence and Statistical Hadronisation Models (SHM).
The production of the hypertriton nuclei 3ΛH and 3Λ¯H¯¯¯¯ has been measured for the first time in Pb-Pb collisions at sNN−−−√ = 2.76 TeV with the ALICE experiment at LHC energies. The total yield, dN/dy ×B.R.(3ΛH→3He,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0-10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3 = 3ΛH/(3He ×Λ/p) was measured to be S3 = 0.60 ± 0.13 (stat.) ± 0.21 (syst.) in 0-10% centrality events; this value is compared to different theoretical models. The measured S3 is fully compatible with thermal model predictions. The measured 3ΛH lifetime, τ=181+54−39(stat.)±33(syst.) ps is compatible within 1σ with the world average value.
The production of the hypertriton nuclei 3ΛH and 3Λ¯H¯¯¯¯ has been measured for the first time in Pb-Pb collisions at sNN−−−√ = 2.76 TeV with the ALICE experiment at LHC energies. The total yield, dN/dy ×B.R.(3ΛH→3He,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0-10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3 = 3ΛH/(3He ×Λ/p) was measured to be S3 = 0.60 ± 0.13 (stat.) ± 0.21 (syst.) in 0-10% centrality events; this value is compared to different theoretical models. The measured S3 is fully compatible with thermal model predictions. The measured 3ΛH lifetime, τ=181+54−39(stat.)±33(syst.) ps is compatible within 1σ with the world average value.
The production of the hypertriton nuclei HΛ3 and H‾Λ¯3 has been measured for the first time in Pb–Pb collisions at sNN=2.76 TeV with the ALICE experiment at LHC. The pT-integrated HΛ3 yield in one unity of rapidity, dN/dy×B.R.(HΛ3→He3,π−)=(3.86±0.77(stat.)±0.68(syst.))×10−5 in the 0–10% most central collisions, is consistent with the predictions from a statistical thermal model using the same temperature as for the light hadrons. The coalescence parameter B3 shows a dependence on the transverse momentum, similar to the B2 of deuterons and the B3 of 3He nuclei. The ratio of yields S3=HΛ3/(He3×Λ/p) was measured to be S3=0.60±0.13(stat.)±0.21(syst.) in 0–10% centrality events; this value is compared to different theoretical models. The measured S3 is compatible with thermal model predictions. The measured HΛ3 lifetime, τ=181−39+54(stat.)±33(syst.)ps is in agreement within 1σ with the world average value.
An improved value for the lifetime of the (anti-)hypertriton has been obtained using the data sample of Pb-Pb collisions at sNN−−−√= 5.02 TeV collected by the ALICE experiment at the LHC. The (anti-)hypertriton has been reconstructed via its charged two-body mesonic decay channel and the lifetime has been determined from an exponential fit to the dN/d(ct) spectrum. The measured value, τ = 242+34−38 (stat.) ± 17 (syst.) ps, is compatible with all the available theoretical predictions, thus contributing to the solution of the longstanding hypertriton lifetime puzzle.
An improved value for the lifetime of the (anti-)hypertriton has been obtained using the data sample of Pb-Pb collisions at sNN−−−√= 5.02 TeV collected by the ALICE experiment at the LHC. The (anti-)hypertriton has been reconstructed via its charged two-body mesonic decay channel and the lifetime has been determined from an exponential fit to the dN/d(ct) spectrum. The measured value, τ = 242+34−38 (stat.) ± 17 (syst.) ps, is compatible with all the available theoretical predictions, thus contributing to the solution of the longstanding hypertriton lifetime puzzle.
Here we present a formal description of Biremis panamae Barka, Witkowski et Weisenborn sp. nov., which was isolated from the marine littoral environment of the Pacific Ocean coast of Panama. The description is based on morphology (light and electron microscopy) and the rbcL, psbC and SSU sequences of one clone of this species. The new species is included in Biremis due to its morphological features; i.e. two marginal rows of foramina, chambered striae, and girdle composed of numerous punctate copulae. The new species also possesses a striated valve face which is not seen in most known representatives of marine littoral Biremis species. In this study we also present the relationship of Biremis to other taxa using morphology, DNA sequence data and observations of auxosporulation. Our results based on these three sources point to an evolutionary relationship between Biremis, Neidium and Scoliopleura. The unusual silicified incunabular caps present in them are known otherwise only in Muelleria, which is probably related to the Neidiaceae and Scoliotropidaceae. We also discuss the relationship between Biremis and the recently described Labellicula and Olifantiella.
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).
Methods: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Major secondary objectives, also at week 24, were to evaluate whether IXE was: (1) non-inferior to ADA for achievement of ACR50 and (2) superior to ADA for PASI100 response. Additional PsA, skin, treat-to-target and quality-of-life outcome measures were assessed at week 24.
Results: The primary efficacy endpoint was met (IXE: 36%, ADA: 28%; p=0.036). IXE was non-inferior for ACR50 response (IXE: 51%, ADA: 47%; treatment difference: 3.9%) and superior for PASI100 response (IXE: 60%, ADA: 47%; p=0.001). IXE had greater response versus ADA in additional PsA, skin, nail, treat-to-target and quality-of-life outcomes. Serious adverse events were reported in 8.5% (ADA) and 3.5% (IXE) of patients.
Conclusions: IXE was superior to ADA in achievement of simultaneous improvement of joint and skin disease (ACR50 and PASI100) in patients with PsA and inadequate response to csDMARDs. Safety and tolerability for both biologicals were aligned with established safety profiles.